ESPE Abstracts

Central precocious puberty (CPP) may have endocrine and metabolic implications in adulthood. Long-term effects may be associated with the underlying neuroendocrine dysfunction leading to CPP, the GnRH analogue (GnRHa) therapy, or both. Data are conflicting on the long-term risk of polycystic ovarian syndrome in both treated and untreated women. Clinical hyperandrogenism has been more frequently reported in CPP women than in controls, with no significant difference between GnRHa-treated and untreated CPP women. Gonadal function is promptly restored in girls after cessation of treatment and reproductive potential appears normal in young adulthood. However, the assisted- fertilization rate may be higher in untreated CPP women than in treated CPP women, suggesting that pubertal suppression treatment may have a protective effect. CPP (treated or untreated) is not associated with increased risk of obesity, metabolic derangements, or cancer morbidities in young adulthood. Moreover, GnRHa therapy does not seem to have any long-term effect on BMI or a negative impact on BMD. The finding that the health status of former CPP women is similar to that of the general population is reassuring.